UTokyo Innovation Platform - aVenture Asset Manager Research
Location
Tokyo, JP
Founded
2016
UTokyo Innovation Platform focuses on accelerating global innovation through investments in early-stage startups, particularly those emerging from the University of Tokyo ecosystem. As a wholly-owned subsidiary of the University of Tokyo, the firm primarily targets Series A rounds, with occasional participation in later stages. Their investment strategy spans various sectors, with a notable emphasis on biotechnology and life sciences.
The firm's portfolio includes promising companies such as Axial Therapeutics, Carbon Biosciences, and DEM Biopharma, all of which have raised significant capital. UTokyo Innovation Platform offers comprehensive support to startups, including investment, mentorship, and access to the university's vast research resources. Their unique position as a university-affiliated investor allows them to bridge academic research with commercial applications, fostering innovation and global competitiveness.
UTokyo Innovation Platform - Portfolio Snapshot
Portfolio activity breakdown across disclosed investments and stages
Portfolio Companies6
Current Portfolio Count6
Top Investment Stages
Series A3 (50.0%)
Series C2 (33.3%)
Seed1 (16.7%)
Stage Mix
Series A 50%Series C 33%Seed 17%
Concentration shown as share of disclosed investments by stage.